paclitaxel has been researched along with Cryptosporidiosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, M; Wang, D; Wu, X; Yang, B; Yin, J; Zhu, G | 1 |
| Wang, D; Yan, Y; Yang, B; Yin, J; Zhang, Y; Zhu, G | 1 |
2 other study(ies) available for paclitaxel and Cryptosporidiosis
| Article | Year |
|---|---|
Host cells with transient overexpression of MDR1 as a novel in vitro model for evaluating on-target effect for activity against the epicellular Cryptosporidium parasite.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cryptosporidiosis; Cryptosporidium parvum; Doxorubicin; Humans; Paclitaxel | 2021 |
On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target.
Topics: Algorithms; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cryptosporidiosis; Cryptosporidium; Cryptosporidium parvum; Humans; Paclitaxel; Parasites | 2023 |